Bioavailability (BA) measures the rate and extent a drug reaches systemic circulation, while Bioequivalence (BE) determines whether two drug products produce comparable exposure profiles.
BA/BE studies are essential in generic drug development and formulation changes. Regulatory authorities require statistical demonstration of equivalence to ensure therapeutic consistency. These studies support product approval and labeling decisions.